TRAIL-R2/Fc Chimera

GENTAUR BVBA

VAT BE0473327336

Av. de l Armee 68 B4

1040 Brussels BELGIUM

Tel + 32 16 58 90 45

Fax + 32 16 50 90 45

GENTAUR France SARL

SIRET 48423788800017

Rue Lagrange, 9

75005 Paris, France

Tel 01 43 25 01 50

Fax 01 43 25 01 60

GENTAUR Germany

52074 Aachen, Germany

Tel +32 16 58 90 45

Fax +32 16 50 90 45

GENTAUR Pol Sp. Z.o.o. Ulica Ogarna 15/19B m2

80-826 GDANSK

Tel 00 48 51 760 77 08

Fax: 00 32 16 50 90 45

GENTAUR Italy

23015 Milano, Italy

Tel 02 36 00 65 93

Fax 02 36 00 65 94

Česká republika Praha
+420246019719

Danmark

+4569918806

Finland Helsset
+358942419041

Ελλάς Αθήνα
+302111768494

Ireland Dublin
+35316526556

Luxembourg
+35220880274

Magyarország Budapest
+3619980547

Nederland
+31208080893

Norge Oslo
+4721031366

Österreich
+43720880899

Sverige Stockholm
+46852503438

Schweiz Züri
+41435006251

Northern America

Canada Montreal
+15149077481

US New York
+17185132983

Source:

Produced in HEK 293 cells. The extracellular domain of human TRAIL-R2 (aa 1 - 182) is fused to the Fc portion of human IgG1.

Description:

DR5 is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

Applications:

Loading control

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Example Data:

Fig. 1. SDS-PAGE

Fig.1. SDS-PAGE Electrophoresis of TRAIL-R2 (DR5) / Fc recombinant protein (separating gel, 6% stacking gel; reducing conditions).
Lane 1 to 4: TRAIL-R2 (DR5)/ Fc recombinant protein (2000 ng, 1000 ng, 500 ng, 200 ng per lane). Staining with Coomasie Blue.

Fig.2. Western Blotting

Fig.2. Western Blotting of TRAIL-R2 (DR5) / Fc recombinant protein. Reducing conditions.
Lane 1 to 4: immunostaining with TRAIL-R2 (DR5) specific antibody DR5-01 (Cat. No. 11-461-C100; dilution 2 μg/ml ). Detection with Goat anti mouse / HRP secondary antibody. Amount of TRAIL-R2 (DR5)/ Fc recombinant protein loaded on each lane: (1) 50 ng, (2) 100 ng, (3) 200 ng, (4) 500 ng.